{"entity":{"id":"genelux","kind":"company","name":"Genelux","aka":["Genelux Corporation"],"tldr":"Genelux is a United States-based biotechnology company running 2 late-stage cancer trials of olvimulogene nanivacirepvec and Olvimulogene nanivacirepvec in ovarian cancer and non-small-cell lung cancer.","summary":"Genelux, based in Westlake Village, CA, the United States, is a biotechnology company. Genelux is a biopharmaceutical company developing oncolytic immunotherapies based on a modified vaccinia virus platform. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials (1 in phase 3), testing olvimulogene nanivacirepvec and Olvimulogene nanivacirepvec in ovarian cancer and non-small-cell lung cancer. The largest, NCT05281471 (Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)), plans to enrol 186 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-11","wikipedia":"https://en.wikipedia.org/wiki/Genelux_Corporation","links":[{"label":"Official website","url":"https://www.genelux.com"},{"label":"ClinicalTrials.gov: trials led by Genelux","url":"https://clinicaltrials.gov/search?lead=Genelux%20Corporation"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["ovarian","nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":["olvimulogene-nanivacirepvec"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06463665"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Westlake Village, CA","country":"US","companyType":"biotech","website":"https://www.genelux.com","stage":"public","investors":[],"funding":[]},"route":"/companies/genelux/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"}],"drug":[{"id":"olvimulogene-nanivacirepvec","kind":"drug","name":"Olvimulogene nanivacirepvec","route":"/drugs/olvimulogene-nanivacirepvec/"}],"trial":[{"id":"nct05281471","kind":"trial","name":"Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)","route":"/trials/nct05281471/"},{"id":"nct06463665","kind":"trial","name":"Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL ","route":"/trials/nct06463665/"}]}}